Viridian Q3 net loss $47.7M; new CEO Mahoney; cash runway into 2026 after $185M placement

Viridian Therapeutics, Inc.\DE

2023-Q3 EPS reported -$3.97 revenue$242,000

Net loss $47.7M vs $28.9M YoY; R&D $30.4M (+$8.3M) and G&A $20.9M (+$12.0M).
Cash, equivalents & ST investments $313M at Sep 30; closed $185M private placement Nov 1 extending runway into 2026.
Stephen Mahoney appointed President/CEO in Oct; new COO Thomas Beetham and CBO Shan Wu also hired.
THRIVE (active TED) and THRIVE-2 (chronic) Phase 3 trials on track; topline mid-2024 and year-end 2024 respectively.
Subcutaneous program selection by year-end 2023; Phase 1 data for VRDN-001/002/003 expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Viridian Therapeutics, Inc.\DE reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the quarter ended September 30, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-276007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.